As of Mar 31
| -2.70 / -2.67%|
The 27 analysts offering 12-month price forecasts for Novartis have a median target of 104.47, with a high estimate of 119.20 and a low estimate of 67.92. The median estimate represents a +5.94% increase from the last price of 98.61.
The current consensus among 30 polled investment analysts is to Buy stock in Novartis. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.